Alnylam Pharmaceuticals Trading Volume Drops 51% to $189 Million, Ranks 490th in Market Activity

On May 2, 2025, Alnylam Pharmaceuticals (ALNY) saw a trading volume of $189 million, a 51.41% decrease from the previous day, ranking 490th in the day's stock market activity. The stock price increased by 1.67%.

Alnylam Pharmaceuticals reported a 28% year-over-year growth in global net product revenues for the first quarter of 2025, reaching $469 million. This growth was driven by strong performances from AMVUTTRA and ONPATTRO, which generated $310 million and $49 million in revenues, respectively, marking a 36% increase compared to the same period last year.

During the first quarter of 2025, Alnylam Pharmaceuticals reported an adjusted loss of $0.01 per share, which was significantly narrower than the estimated loss of $0.56 per share. This positive financial performance was highlighted during the company's earnings call, where key executives, including Yvonne Greenstreet, the Chief Executive Officer, and Jeff Poulton, the Chief Financial Officer, provided updates on the company's commercial progress, pipeline updates, and clinical developments.